Piper Jaffray analyst Edward Tenthoff is confident in Braftovi plus Mektovi approval in BRAF-mutant melanoma by the June 30 FDA action date. Array BioPharma presented at ASCO Phase III data showing median overall survival of 33.6 months for the combo versus 16.9 months for Zelboraf control, Tenthoff tells investors in a research note. This "best-in-class efficacy and tolerability will differentiate the combo on launch," the analyst contends. He recommends buying Array shares by June 30 and reiterates an Overweight rating on the name with a $21 price target.

Mizuho lowered the firm's price target on Array Technologies to $16 from $18 and keeps a Neutral rating on the shares. The firm's Q1 clean energy estimates are mostly in line with company guidance and consensus, saying most companies reset expectations on the Q4 earnings call and had good visibility for the quarter. The analyst says Mizuho's most significant change in its quarterly preview is regarding Q2 results for the residential solar and inverter names. The firm expects Q2 installs to be down quarter-over-quarter verses consensus assuming a Q1 trough, based on permitting data which show Q2 MWs down 7% quarter-over-quarter. Mizuho's sector preference for utility solar over residential solar is unchanged.